IL-22R Ligands IL-20, IL-22, and IL-24 Promote Wound Healing in Diabetic db/db Mice

PLoS One. 2017 Jan 26;12(1):e0170639. doi: 10.1371/journal.pone.0170639. eCollection 2017.

Abstract

Diabetic foot ulcers (DFU) are one of the major complications in type II diabetes patients and can result in amputation and morbidity. Although multiple approaches are used clinically to help wound closure, many patients still lack adequate treatment. Here we show that IL-20 subfamily cytokines are upregulated during normal wound healing. While there is a redundant role for each individual cytokine in this subfamily in wound healing, mice deficient in IL-22R, the common receptor chain for IL-20, IL-22, and IL-24, display a significant delay in wound healing. Furthermore, IL-20, IL-22 and IL-24 are all able to promote wound healing in type II diabetic db/db mice. Mechanistically, when compared to other growth factors such as VEGF and PDGF that accelerate wound healing in this model, IL-22 uniquely induced genes involved in reepithelialization, tissue remodeling and innate host defense mechanisms from wounded skin. Interestingly, IL-22 treatment showed superior efficacy compared to PDGF or VEGF in an infectious diabetic wound model. Taken together, our data suggest that IL-20 subfamily cytokines, particularly IL-20, IL-22, and IL-24, might provide therapeutic benefit for patients with DFU.

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / genetics*
  • Diabetes Mellitus, Type 2 / therapy
  • Diabetic Foot / genetics*
  • Diabetic Foot / pathology
  • Diabetic Foot / therapy
  • Gene Expression Regulation
  • Humans
  • Immunoglobulin Fc Fragments / administration & dosage
  • Interleukin-22
  • Interleukins / administration & dosage
  • Interleukins / genetics*
  • Ligands
  • Mice
  • Mice, Inbred NOD
  • Receptors, Interleukin / genetics*
  • Wound Healing / drug effects
  • Wound Healing / genetics*
  • Wound Infection / genetics
  • Wound Infection / therapy

Substances

  • Immunoglobulin Fc Fragments
  • Interleukins
  • Ligands
  • Receptors, Interleukin
  • interleukin-22 receptor
  • interleukin-24
  • interleukin 20

Grants and funding

Other than all the authors, Genentech had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received support in the form of salaries. Genentech has reviewed the manuscript, and may potentially file patents and develop therapies based on part of the data in the manuscript.